



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/927,738	08/10/2001	Tongwen Wang	17633/1082	7298

29933 7590 08/13/2003

PALMER & DODGE, LLP
KATHLEEN M. WILLIAMS
111 HUNTINGTON AVENUE
BOSTON, MA 02199

EXAMINER

CARLSON, KAREN C

ART UNIT PAPER NUMBER

1653

DATE MAILED: 08/13/2003

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/927,738

Applicant(s)

WANG, TONGWEN

Examiner

Karen Cochran Carlson, Ph.D.

Art Unit

1653

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-43 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-43 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on ____ is: a) ☐ approved b) ☐ disapproved by the Examiner.
- If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).
- a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) ____.
- 4) ☐ Interview Summary (PTO-413) Paper No(s) ____.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: _____.

Art Unit: 1653

Restriction to one of the following inventions is required under 35 U.S.C. 121:

1. Claims 1-3, drawn to polynucleotides having SEQ ID NO: 10 (clone S3-1), classified in class 536, subclass 23.1.
2. Claims 1-3, drawn to polynucleotides having SEQ ID NO: 12 (clone S3-12), classified in class 536, subclass 23.1.
3. Claims 1-3, drawn to polynucleotides having SEQ ID NO: 14 (clone S3-103), classified in class 536, subclass 23.1.
4. Claims 1-3, drawn to polynucleotides having SEQ ID NO: 16 (clone S3-125), classified in class 536, subclass 23.1.
5. Claims 1-3, drawn to polynucleotides having SEQ ID NO: 18 (clone S3+30), classified in class 536, subclass 23.1.
6. Claims 1-3, drawn to polynucleotides having SEQ ID NO: 20 (clone S3-14; 5'), classified in class 536, subclass 23.1.
7. Claims 1-3, drawn to polynucleotides having SEQ ID NO: 20 (clone S3-14; 3'), classified in class 536, subclass 23.1.
8. Claim 5 and 8, drawn to polypeptide having SEQ ID NO: 1 and compositions comprising SMAD1, classified in class 530, subclass 350.
9. Claim 5 and 8, drawn to polypeptide having SEQ ID NO: 2 (S1+28) and compositions comprising SMAD1, classified in class 530, subclass 350.
10. Claim 5, 8, and 9, drawn to polypeptide having SEQ ID NO: 3 or NO: 5 (S1+19) and compositions comprising SMAD1 or SMAD2, classified in class 530, subclass 350.
11. Claim 5 and 8, drawn to polypeptide having SEQ ID NO: 7 (S1+12) and compositions comprising SMAD1, classified in class 530, subclass 350.
12. Claim 5, drawn to polypeptide having SEQ ID NO: 8 (S1+12-2), classified in class 530, subclass 350.
13. Claim 5, drawn to polypeptide having SEQ ID NO: 9 (S1+12-5), classified in class 530, subclass 350.
14. Claims 4, 5, 8, and 10, drawn to polypeptide having SEQ ID NO: 11 (S3-1) and compositions comprising SMAD1 or SMAD3, classified in class 530, subclass 350.
15. Claims 4, 5, 8 and 10, drawn to polypeptide having SEQ ID NO: 13 (S3-12) and compositions comprising SMAD1 or SMAD3, classified in class 530, subclass 350.
16. Claims 4, 5, 8, and 10, drawn to polypeptide having SEQ ID NO: 15 (S3-103) and compositions comprising SMAD1 or SMAD3, classified in class 530, subclass 350.
17. Claims 4, 5, and 10, drawn to polypeptide having SEQ ID NO: 17 (S3-125) and compositions comprising SMAD3, classified in class 530, subclass 350.
18. Claims 4, 5, and 8, drawn to polypeptide having SEQ ID NO: 19 (S3+30) and compositions comprising SMAD1, classified in class 530, subclass 350.
19. Claims 4, 5, and 10, drawn to polypeptide having SEQ ID NO: 22 (S3+14) and compositions comprising SMAD3, classified in class 530, subclass 350.
20. Claim 7, drawn to an antibody against polypeptide having SEQ ID NO: 1, classified in class 530, subclass 387.1.
21. Claim 7, drawn to an antibody against polypeptide having SEQ ID NO: 2 (S1+28), classified in class 530, subclass 387.1.
22. Claim 7, drawn to an antibody against polypeptide having SEQ ID NO: 3 or NO: 5 (S1+19), classified in class 530, subclass 387.1.

Art Unit: 1653

23. Claim 5, drawn to an antibody against polypeptide having SEQ ID NO: 7 (S1+12), classified in class 530, subclass 387.1.
24. Claim 7, drawn to an antibody against polypeptide having SEQ ID NO: 8 (S1+12-2), classified in class 530, subclass 387.1.
25. Claim 7, drawn to an antibody against polypeptide having SEQ ID NO: 9 (S1+12-5), classified in class 530, subclass 387.1.
26. Claims 6 and 7, drawn to an antibody against polypeptide having SEQ ID NO: 11 (S3-1), classified in class 530, subclass 387.1.
27. Claims 6 and 7, drawn to an antibody against polypeptide having SEQ ID NO: 13 (S3-12), classified in class 530, subclass 387.1.
28. Claims 6 and 7, drawn to an antibody against polypeptide having SEQ ID NO: 15 (S3-103), classified in class 530, subclass 387.1.
29. Claims 6 and 7, drawn to an antibody against polypeptide having SEQ ID NO: 17 (S3-125), classified in class 530, subclass 387.1.
30. Claims 6 and 7, drawn to an antibody against polypeptide having SEQ ID NO: 19 (S3+30), classified in class 530, subclass 387.1.
31. Claims 6 and 7, drawn to an antibody against polypeptide having SEQ ID NO: 22 (S3+14), classified in class 530, subclass 387.1.
32. Claims 8 and 10, drawn to compositions of SMADI or SMAD3 and HsN3, classified in class 514, subclass 2.
33. Claim 8, drawn to compositions of SMADI and antizyme, classified in class 514, subclass 2.
34. Claim 8, drawn to compositions of SMADI and PAG, classified in class 514, subclass 2.
35. Claim 8-10, drawn to compositions of SMADI, SMAD2 or SMAD3 and GST, classified in class 514, subclass 2.
36. Claim 8, drawn to compositions of SMADI and tumor associated gene, classified in class 514, subclass 2.
37. Claims 8-10, drawn to compositions of SMADI, SMAD2, or SMAD3 and AIP4, classified in class 514, subclass 2.
38. Claim 8, drawn to compositions of SMADI and U1SnRNP, classified in class 514, subclass 2.
39. Claims 8-10, drawn to compositions of SMADI, SMAD2 or SMAD3 and TRIP4, classified in class 514, subclass 2.
40. Claim 8, drawn to compositions of SMADI and Ran GTP binding protein 5, classified in class 514, subclass 2.
41. Claim 8, drawn to compositions of SMADI and PO acidic ribosomal phosphoprotein, classified in class 514, subclass 2.
42. Claim 8, drawn to compositions of SMADI and B-tubulin, classified in class 514, subclass 2.
43. Claims 8-10, drawn to compositions of SMADI, SMAD2, or SMAD3 and KIAA 00104, classified in class 514, subclass 2.
44. Claims 8 and 10, drawn to compositions of SMADI or SMAD3 and HsN3, classified in class 514, subclass 2.
45. Claim 10, drawn to compositions of SMAD3 and HEF1, classified in class 514, subclass 2.
46. Claim 10, drawn to compositions of SMAD3 and FKBP25, classified in class 514, subclass 2.

Art Unit: 1653

47. Claim 10, drawn to compositions of SMAD3 and SnRNP C, classified in class 514, subclass 2.
48. Claim 10, drawn to compositions of SMAD3 and RBP2, classified in class 514, subclass 2.
49. Claim 10, drawn to compositions of SMAD3 and hnRNP A1, classified in class 514, subclass 2.
50. Claim 10, drawn to compositions of SMAD3 and SEQ ID NO: 4, classified in class 514, subclass 2.
51. Claim 40 and 41, drawn to compositions of SMAD1, HsN3, and antizyme, classified in class 514, subclass 2.
52. Claim 42, drawn to compositions HsN3 and antizyme, classified in class 514, subclass 2.
53. Claim 42, drawn to compositions HsN3 and ubiquitin, classified in class 514, subclass 2.
54. Claim 42, drawn to compositions HsN3 and HEF1, classified in class 514, subclass 2.
55. Claim 42, drawn to compositions HEF1 and antizyme, classified in class 514, subclass 2.
56. Claim 43, drawn to compositions SNIP1 and CBP/p300, classified in class 514, subclass 2.

Inventions 1-56 comprise overlapping claims. The products presented in these claims differ in structure and in function and therefore are patentably distinct one from the other. If any one of Inventions 1-56 is elected, the claims will be examined only in so far as they pertain to the subject matter of the elected inventions.

57. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and HsN3, classified in class 435, subclass 7.1.
58. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and antizyme, classified in class 435, subclass 7.1.
59. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and PAG, classified in class 435, subclass 7.1.
60. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and GST, classified in class 435, subclass 7.1.
61. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and tumor associated gene, classified in class 435, subclass 7.1.
62. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and AIP4, classified in class 435, subclass 7.1.
63. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and U1SnRNP, classified in class 435, subclass 7.1.
64. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and TRIP1, classified in class 435, subclass 7.1.
65. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and Ran GTP binding protein 5, classified in class 435, subclass 7.1.
66. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and PO acidic ribosomal phosphoprotein, classified in class 435, subclass 7.1.
67. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and B-tubulin, classified in class 435, subclass 7.1.

Art Unit: 1653

68. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and KIAA 00104, classified in class 435, subclass 7.1.
69. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and SEQ ID NO: 1, classified in class 435, subclass 7.1.
70. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and SEQ ID NO: 2, classified in class 435, subclass 7.1.
71. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and SEQ ID NO: 3, classified in class 435, subclass 7.1.
72. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and SEQ ID NO: 7, classified in class 435, subclass 7.1.
73. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and SEQ ID NO: 11, classified in class 435, subclass 7.1.
74. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and SEQ ID NO: 13, classified in class 435, subclass 7.1.
75. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and SEQ ID NO: 15, classified in class 435, subclass 7.1.
76. Claims 11, 12, and 18-20, drawn to a screening assay involving the interaction of SMAD1 and SEQ ID NO: 19, classified in class 435, subclass 7.1.
77. Claims 11, 13, and 18-20, drawn to a screening assay involving the interaction of SMAD2 and GST, classified in class 435, subclass 7.1.
78. Claims 11, 13, and 18-20, drawn to a screening assay involving the interaction of SMAD2 and AIP4, classified in class 435, subclass 7.1.
79. Claims 11, 13, and 18-20, drawn to a screening assay involving the interaction of SMAD2 and TRIP4, classified in class 435, subclass 7.1.
80. Claims 11, 13, and 18-20, drawn to a screening assay involving the interaction of SMAD2 and KIAA00104, classified in class 435, subclass 7.1.
77. Claims 11, 13, and 18-20, drawn to a screening assay involving the interaction of SMAD2 and SEQ ID NO: 3, classified in class 435, subclass 7.1.
78. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and HsN3, classified in class 435, subclass 7.1.
79. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and KIAA 00104, classified in class 435, subclass 7.1.
80. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and HEF1, classified in class 435, subclass 7.1.
81. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and FKBP25, classified in class 435, subclass 7.1.
82. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and AIP4, classified in class 435, subclass 7.1.
83. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and SnRNP C, classified in class 435, subclass 7.1.
84. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and RBP2, classified in class 435, subclass 7.1.
85. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and TRIP4, classified in class 435, subclass 7.1.
86. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and hnRNP A1, classified in class 435, subclass 7.1.
87. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and GST, classified in class 435, subclass 7.1.

Art Unit: 1653

88. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and SEQ ID NO: 11, classified in class 435, subclass 7.1.
89. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and SEQ ID NO: 15, classified in class 435, subclass 7.1.
90. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and SEQ ID NO: 13, classified in class 435, subclass 7.1.
91. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and SEQ ID NO: 4, classified in class 435, subclass 7.1.
92. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and SEQ ID NO: 17, classified in class 435, subclass 7.1.
93. Claims 11, 14, and 18-20, drawn to a screening assay involving the interaction of SMAD3 and SEQ ID NO: 22, classified in class 435, subclass 7.1.
94. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and antizyme, classified in class 435, subclass 7.1.
95. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and GST, classified in class 435, subclass 7.1.
96. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and PAG, classified in class 435, subclass 7.1.
97. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and FKBP25, classified in class 435, subclass 7.1.
98. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and TRIP\$, classified in class 435, subclass 7.1.
99. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and HEF1, classified in class 435, subclass 7.1.
100. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and AIP4, classified in class 435, subclass 7.1.
101. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and SnRNPC, classified in class 435, subclass 7.1.
102. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and TGF-B Type II receptors, classified in class 435, subclass 7.1.
103. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and BMP Type I receptor ALK3, classified in class 435, subclass 7.1.
104. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and FN1A, classified in class 435, subclass 7.1.
105. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and GGTB, classified in class 435, subclass 7.1.
106. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and KIAA 00104, classified in class 435, subclass 7.1.
107. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and SEQ ID NO: 1, classified in class 435, subclass 7.1.
108. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and SEQ ID NO: 2, classified in class 435, subclass 7.1.
109. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and SEQ ID NO: 3, classified in class 435, subclass 7.1.
110. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and SEQ ID NO: 7, classified in class 435, subclass 7.1.
111. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and SEQ ID NO: 11, classified in class 435, subclass 7.1.

Art Unit: 1653

112. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and SEQ ID NO: 13, classified in class 435, subclass 7.1.
113. Claims 11, 15, and 18-20, drawn to a screening assay involving the interaction of HsN3 and SEQ ID NO: 22, classified in class 435, subclass 7.1.
114. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and enolase, classified in class 435, subclass 7.1.
115. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and PAG, classified in class 435, subclass 7.1.
116. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and tumor associated gene, classified in class 435, subclass 7.1.
117. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and hn RNP A1, classified in class 435, subclass 7.1.
118. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and TRIP4, classified in class 435, subclass 7.1.
119. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and AIP4, classified in class 435, subclass 7.1.
120. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and HEF1, classified in class 435, subclass 7.1.
121. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and SNRNP C, classified in class 435, subclass 7.1.
122. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and KIAA 00104, classified in class 435, subclass 7.1.
123. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and HnRNPA1, classified in class 435, subclass 7.1.
124. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and SEQ ID NO: 1, classified in class 435, subclass 7.1.
125. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and SEQ ID NO: 2, classified in class 435, subclass 7.1.
126. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and SEQ ID NO: 3, classified in class 435, subclass 7.1.
127. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and SEQ ID NO: 7, classified in class 435, subclass 7.1.
128. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and SEQ ID NO: 11, classified in class 435, subclass 7.1.
129. Claims 11, 16, and 18-20, drawn to a screening assay involving the interaction of antizyme and SEQ ID NO: 22, classified in class 435, subclass 7.1.
130. Claims 11, 17, and 18-20, drawn to a screening assay involving the interaction of SEQ ID NO: 3 and HsN3, classified in class 435, subclass 7.1.
131. Claims 11, 17, and 18-20, drawn to a screening assay involving the interaction of SEQ ID NO: 3 and antizyme, classified in class 435, subclass 7.1.
132. Claims 11, 17, and 18-20, drawn to a screening assay involving the interaction of SEQ ID NO: 3 and SEQ ID NO: 7, classified in class 435, subclass 7.1.
133. Claims 11, 17, and 18-20, drawn to a screening assay involving the interaction of SEQ ID NO: 3 and AIP4, classified in class 435, subclass 7.1.
134. Claims 11, 17, and 18-20, drawn to a screening assay involving the interaction of SEQ ID NO: 3 and cytoplasmic domain of ALK2 classified in class 435, subclass 7.1.

Art Unit: 1653

135. Claims 11, 17, and 18-20, drawn to a screening assay involving the interaction of SEQ ID NO: 3 and cytoplasmic domain of ALK5 classified in class 435, subclass 7.1.

Inventions 57-135 encompass the broad generic receptor binding assay or enzymatic assay as set forth in Claim 11. On its face, this claimed assay is not novel, but such is beyond the scope of a restriction requirement. The dependent claims recite products having differing structure and function one from the other and therefore a method using one set of products is different from a method using another set of products. If anyone of Inventions 57-136 is elected, the generic claim of Claim 11 and the subject matter of the elected invention will be examined.

136. Claims 21-24, drawn to method of identifying compounds using recombinant techniques, classified in class 435, subclass 6.
137. Claims 25-30, drawn to method of identifying compounds via recombinant expression of an enzyme, classified in class 435, subclass 183.
138. Claims 31, drawn to method of monitoring proteasome-mediated proteolysis, classified in class 530, subclass 401.
139. Claims 32-35 and 37, drawn to method of identifying compounds which modulate proteolysis via recombinant techniques, classified in class 435, subclass 7.1.
140. Claims 36, drawn to method of monitoring proteolysis using recombinant techniques, classified in class 435, subclass 6.
141. Claims 38 and 39, drawn to method of identifying SMAD interactors using recombinant techniques, classified in class 435, subclass 6.

The inventions are distinct, each from the other because of the following reasons:

Inventions 1-56 are drawn to products that differ in composition, structure, and function.

Therefore, these Inventions are patentably distinct one from the other.

The methods of Inventions 57-141 require the use of different products, comprise different method steps, and/or have different goals and outcomes. Therefore, the methods of Inventions 57-141 are patentably distinct.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Art Unit: 1653


Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a petition under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 703-308-0034. The examiner can normally be reached on 7:30 AM - 5:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low can be reached on 703-308-2329. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-4242 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

August 8, 2003


KAREN COCHRANE CARLSON, PH.D.
PRIMARY EXAMINER